{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=22",
    "query": {
      "intervention": "Placebo Administration first",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1736,
    "total_pages": 174,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T15:47:58.701Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02534038",
      "title": "Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Disinhibition Syndrome"
      ],
      "interventions": [
        {
          "name": "AVP-786",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-12-01",
      "completion_date": "2017-10-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02534038"
    },
    {
      "nct_id": "NCT01568203",
      "title": "First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "AMG 579",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-09",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-10-10",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01568203"
    },
    {
      "nct_id": "NCT01010204",
      "title": "Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Smoking Cessation",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K.N. Roy Chengappa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2010-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2017-12-04",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 2,
      "location_summary": "DuBois, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "DuBois",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010204"
    },
    {
      "nct_id": "NCT00957164",
      "title": "Treatment of Post-Traumatic Stress Disorder (PTSD) and Chronic Pain After Traumatic Orthopedic Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pain",
        "Post-traumatic Stress Disorder"
      ],
      "interventions": [
        {
          "name": "Brief Prolonged Exposure Protocol",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Chronic Pain Management Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Self-Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas at Arlington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 51,
      "start_date": "2009-08",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-01-31",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 4,
      "location_summary": "Arlington, Texas • Fort Sam Houston, Texas • Lackland Air Force Base, Texas + 1 more",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        },
        {
          "city": "Lackland Air Force Base",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957164"
    },
    {
      "nct_id": "NCT01944046",
      "title": "Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "Double blind phase Placebo Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "double Blind Oxytocin Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Open Label intranasal oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Linmarie Sikich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 290,
      "start_date": "2014-08-01",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • New York, New York • White Plains, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01944046"
    },
    {
      "nct_id": "NCT03139604",
      "title": "GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Graft-versus-host Disease (GVHD)"
      ],
      "interventions": [
        {
          "name": "Itacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 439,
      "start_date": "2017-07-19",
      "completion_date": "2020-07-13",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 49,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 38 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03139604"
    },
    {
      "nct_id": "NCT02178696",
      "title": "Predictors of Antidepressant Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Placebo, identified as placebo to participants",
          "type": "OTHER"
        },
        {
          "name": "Celexa or other antidepressant as clinically indicated",
          "type": "DRUG"
        },
        {
          "name": "Placebo, identifed to participants as \"Active medication\"",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 44,
      "start_date": "2011-01",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178696"
    },
    {
      "nct_id": "NCT03522246",
      "title": "A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal",
        "Fallopian Tube Cancer",
        "Newly Diagnosed",
        "FIGO Stage III-IV",
        "Partial Response",
        "Complete Response"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1097,
      "start_date": "2018-05-14",
      "completion_date": "2030-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 64,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522246"
    },
    {
      "nct_id": "NCT03401073",
      "title": "IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Idiopathic Peripheral Neuropathy"
      ],
      "interventions": [
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2018-09-01",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401073"
    },
    {
      "nct_id": "NCT00780962",
      "title": "N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Radiocontrast Nephropathy"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine (NAC)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium-chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 399,
      "start_date": "2007-10-16",
      "completion_date": "2010-08-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-11-15T15:47:58.701Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00780962"
    }
  ]
}